Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Hisamitsu Pharmaceutical Co / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hisamitsu-pharmaceutical-co" target="_blank" data-smartkarma-citation="entities:17008:1" rel="noopener">Hisamitsu Pharmaceutical Co (4530 JP)</a> reported revenue of ¥34.7B in 1HFY26 down 1% YoY, mainly dragged by subdued performance by Salonpas focused OTC pharmaceutical products.</li>
<li>Rx business revenues grew 6% as Zicthoru, Apohide, Combipatch,Vivelle-Dot etc clocked healthy numbers excepting Mohrus product line.</li>
<li>Hisamitsu reiterated FY26 guidance expecting revenue to be ¥165B with profits growth expected to decelerate on higher cost.</li>
</ul>



Hisamitsu Pharmaceutical Co (4530 JP) reported revenue of ¥34.7B in 1HFY26 down 1% YoY, mainly dragged by subdued performance by Salonpas focused OTC pharmaceutical products.
Rx business revenues grew 6% as Zicthoru, Apohide, Combipatch,Vivelle-Dot etc clocked healthy numbers excepting Mohrus product line.
Hisamitsu reiterated FY26 guidance expecting revenue to be ¥165B with profits growth expected to decelerate on higher cost.


Hisamitsu Pharma (4530 JP): New Products Take Mantle as Salonpas, Mohrus Slows, Guidance Reiterated

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hisamitsu-pharmaceutical-co" target="_blank" data-smartkarma-citation="entities:17008:1" rel="noopener">Hisamitsu Pharmaceutical Co (4530 JP)</a> Q1FY26 revenue of ¥34.7B down 3% YoY, mainly driven by subdued performance in Salonpas focused OTC pharmaceutical products.</li>
<li>Rx business revenues grew 7% as Zicthoru, Apohide, Combipatch,Vivelle-Dot etc clocked healthy numbers excepting Mohrus product line.</li>
<li>Hisamitsu reiterated FY26 guidance expecting revenue to be ¥165B with profits growth expected to decelerate on higher cost.</li>
</ul>



Hisamitsu Pharmaceutical Co (4530 JP) Q1FY26 revenue of ¥34.7B down 3% YoY, mainly driven by subdued performance in Salonpas focused OTC pharmaceutical products.
Rx business revenues grew 7% as Zicthoru, Apohide, Combipatch,Vivelle-Dot etc clocked healthy numbers excepting Mohrus product line.
Hisamitsu reiterated FY26 guidance expecting revenue to be ¥165B with profits growth expected to decelerate on higher cost.


Hisamitsu Pharmaceutical (4530 JP): Guidance Reiterated Amid Seemingly Temporary Hiccup in Q1FY26

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hisamitsu-pharmaceutical-co" target="_blank" data-smartkarma-citation="entities:17008:1" rel="noopener">Hisamitsu Pharmaceutical Co (4530 JP)</a> announced strong Q1FY24 result, with double-digit top-line and triple-digit bottom-line growth, driven by its largest selling OTC product, Salonpas. The company has reiterated FY24 guidance.</li>
<li>In Q1FY24, Hisamitsu has launched Apohide Lotion in Japan for the treatment of primary palmar hyperhidrosis and Xelstrym transdermal system in the U.S. for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).</li>
<li>Hisamitsu has announced buyback of up to 2M of its shares (representing 2.57% of issued shares) from July 2023 to February 2024 for ¥10B.</li>
</ul>



Hisamitsu Pharmaceutical Co (4530 JP) announced strong Q1FY24 result, with double-digit top-line and triple-digit bottom-line growth, driven by its largest selling OTC product, Salonpas. The company has reiterated FY24 guidance.
In Q1FY24, Hisamitsu has launched Apohide Lotion in Japan for the treatment of primary palmar hyperhidrosis and Xelstrym transdermal system in the U.S. for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
Hisamitsu has announced buyback of up to 2M of its shares (representing 2.57% of issued shares) from July 2023 to February 2024 for ¥10B.


Hisamitsu Pharmaceutical (4530 JP): Strong Result, New Drug Launch, & Share Buyback Brighten Outlook

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hisamitsu-pharmaceutical-co" target="_blank" data-smartkarma-citation="entities:17008:1" rel="noopener">Hisamitsu Pharmaceutical Co (4530 JP)</a> reported double digit revenue growth in FY25 on the back of 16% YoY growth in Salonpas focused OTC pharmaceutical products.</li>
<li>Rx business revenues grew 5% YoY as Zicthoru, Apohide, Combipatch, Vivelle-Dot etc clocked healthy numbers excepting Mohrus product line.</li>
<li>Hisamitsu expects FY26 revenue to be ¥165B, up 6% YoY, driven by new products, with net profit growth to decelerate on higher cost.</li>
</ul>



Hisamitsu Pharmaceutical Co (4530 JP) reported double digit revenue growth in FY25 on the back of 16% YoY growth in Salonpas focused OTC pharmaceutical products.
Rx business revenues grew 5% YoY as Zicthoru, Apohide, Combipatch, Vivelle-Dot etc clocked healthy numbers excepting Mohrus product line.
Hisamitsu expects FY26 revenue to be ¥165B, up 6% YoY, driven by new products, with net profit growth to decelerate on higher cost.


Hisamitsu Pharmaceutical (4530 JP): Salonpas Holds Fort; New Products Ramp-Up; Stable FY26 Expected

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hisamitsu-pharmaceutical-co" target="_blank" data-smartkarma-citation="entities:17008:1" rel="noopener">Hisamitsu Pharmaceutical Co (4530 JP)</a> reported single-digit revenue growth and net profit growth in low-teens during 9MFY25, on the back of 13% YoY growth in Salonpas focused OTC segment.</li>
<li>Rx business revenue grew 4% YoY as new products such as Zicthoru, Apohide, Combipatch, Vivelle-Dot etc clocked healthy numbers.</li>
<li>Hisamitsu raised its FY25 guidance for revenue by 1% to ¥154B, operating profit by 24% to ¥18B, and net profit by 24% to ¥20.5B.</li>
</ul>



Hisamitsu Pharmaceutical Co (4530 JP) reported single-digit revenue growth and net profit growth in low-teens during 9MFY25, on the back of 13% YoY growth in Salonpas focused OTC segment.
Rx business revenue grew 4% YoY as new products such as Zicthoru, Apohide, Combipatch, Vivelle-Dot etc clocked healthy numbers.
Hisamitsu raised its FY25 guidance for revenue by 1% to ¥154B, operating profit by 24% to ¥18B, and net profit by 24% to ¥20.5B.


Hisamitsu Pharmaceutical (4530 JP): Growth Momentum Intact; FY25 Guidance Raised

Japan

HISAMITSU PHARMACEUTICAL CO., INC. produces and sells pharmaceutical products. The Company's main product is anti-inflammatory analgesic plasters and poultices sold under the brand name Salonpas.  Hisamitsu Pharmaceutical exports its products to North America and Southeast Asia.  The Company also researches and develops antibacterial products through its related company, RRF.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Hisamitsu Pharmaceutical Co (4530 JP)

Hisamitsu Pharma (4530 JP): New Products Take Mantle as Salonpas, Mohrus Slows, Guidance Reiterated

Hisamitsu 1HFY26 revenue down 1% YoY. With new products gaining momentum, overseas market delivering growth alongside company’s stable guidance...

Tina Banerjee

Hisamitsu Pharmaceutical (4530 JP): Guidance Reiterated Amid Seemingly Temporary Hiccup in Q1FY26

Hisamitsu's Q1FY26 revenue was down 3% YoY due to subdued performance in Salonpas OTC products. However, FY26 guidance was reiterated as Salonpas...

Tina Banerjee

Hisamitsu Pharmaceutical (4530 JP): Salonpas Holds Fort; New Products Ramp-Up; Stable FY26 Expected

Hisamitsu reported double-digit revenue growth in FY25 driven by Salonpas OTC products. The company expects 6% revenue growth in FY26 with net...

Tina Banerjee

Hisamitsu Pharmaceutical (4530 JP): Growth Momentum Intact; FY25 Guidance Raised

Hisamitsu reported strong 9MFY25 result, mainly driven by Salonpas OTC product and new in Rx products. The company has raised FY25 guidance for...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Hisamitsu Pharma (4530 JP): New Products Take Mantle as Salonpas, Mohrus Slows, Guidance Reiterated

​Hisamitsu 1HFY26 revenue down 1% YoY. With new products gaining momentum, overseas market delivering growth alongside company’s stable guidance...

Tina Banerjee

Hisamitsu Pharmaceutical (4530 JP): Guidance Reiterated Amid Seemingly Temporary Hiccup in Q1FY26

​Hisamitsu's Q1FY26 revenue was down 3% YoY due to subdued performance in Salonpas OTC products. However, FY26 guidance was reiterated as Salonpas...

Tina Banerjee

Hisamitsu Pharmaceutical (4530 JP): Strong Result, New Drug Launch, & Share Buyback Brighten Outlook

In Q1FY24 Hisamitsu recorded double-digit top-line and triple-digit bottom-line growth, driven by Salonpas. The company launched 2 drugs in Japan...

Tina Banerjee

Hisamitsu Pharmaceutical (4530 JP): Salonpas Holds Fort; New Products Ramp-Up; Stable FY26 Expected

​Hisamitsu reported double-digit revenue growth in FY25 driven by Salonpas OTC products. The company expects 6% revenue growth in FY26 with net...

Tina Banerjee

Hisamitsu Pharmaceutical (4530 JP): Growth Momentum Intact; FY25 Guidance Raised

​Hisamitsu reported strong 9MFY25 result, mainly driven by Salonpas OTC product and new in Rx products. The company has raised FY25 guidance for...

Tina Banerjee

Hisamitsu 1HFY26 revenue down 1% YoY. With new products gaining momentum, overseas market delivering growth alongside company’s stable guidance...

Hisamitsu's Q1FY26 revenue was down 3% YoY due to subdued performance in Salonpas OTC products. However, FY26 guidance was reiterated as Salonpas...

Hisamitsu reported double-digit revenue growth in FY25 driven by Salonpas OTC products. The company expects 6% revenue growth in FY26 with net...

Hisamitsu reported strong 9MFY25 result, mainly driven by Salonpas OTC product and new in Rx products. The company has raised FY25 guidance for...